Breaking News

MilliporeSigma Acquires AmpTec

Expands mRNA capabilities for vaccines, treatments and diagnostics.

By: Contract Pharma

Contract Pharma Staff

MilliporeSigma has announced the acquisition of AmpTec, a Hamburg, Germany-based, mRNA contract development and manufacturing organization (CDMO). The deal strengthens MilliporeSigma’s capabilities to develop and manufacture mRNA for its customers for use in vaccines, treatments and diagnostics applicable in Covid-19 and many other diseases. Financial terms were not disclosed.   “The success of mRNA-based vaccines for Covid-19 lays the path to accelerate the development of these ther...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters